An isolated antibody HY29 Fab fragment specifically binds to CXC chemokine receptor-2 (CXCR2), wherein the binding molecule can inhibit binding to interleukin 8 (IL-8). Mapping of the N terminus using linear peptides and alanine scanning of CLIPS peptides derived from the N terminus and ECL3 showed that the minimal epitope for the antibody binding was centered around the 31 PFLLD 35 with the second leucine and the aspartic acid key to the binding interaction.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-050 | Recombinant Anti-Human CXCR2 VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
TAB-002MZ-VHH | Anti-Human CXCR2 Recombinant Antibody (TAB-002MZ-VHH) | FC, Inhib | Single domain antibody |
TAB-004MZ-VHH | Anti-Human CXCR2 Recombinant Antibody (TAB-004MZ-VHH) | ELISA, IHC, FuncS, SPR | Single domain antibody |
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.